These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 39071353)

  • 1. Effects of clinically relevant radionuclides on the activation of a type I interferon response by radiopharmaceuticals in syngeneic murine tumor models.
    Kerr CP; Sheehan-Klenk J; Grudzinski JJ; Adam DP; Nguyen TPT; Ferreira CA; Bates AM; Jin WJ; Kwon O; Olson AP; Lin W; Hyun M; Jagodinsky JC; Powers M; Sriramaneni RN; Clark PA; Shea AG; Rojas HC; Choi C; Massey CF; Zangl LM; Pinchuk AN; Aluicio-Sarduy E; Kim K; Engle JW; Hernandez R; Bednarz BP; Weichert JP; Morris ZS
    bioRxiv; 2024 Jul; ():. PubMed ID: 39071353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy.
    Jagodinsky JC; Jin WJ; Bates AM; Hernandez R; Grudzinski JJ; Marsh IR; Chakravarty I; Arthur IS; Zangl LM; Brown RJ; Nystuen EJ; Emma SE; Kerr C; Carlson PM; Sriramaneni RN; Engle JW; Aluicio-Sarduy E; Barnhart TE; Le T; Kim K; Bednarz BP; Weichert JP; Patel RB; Morris ZS
    Theranostics; 2021; 11(13):6120-6137. PubMed ID: 33995649
    [No Abstract]   [Full Text] [Related]  

  • 3. ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models.
    Jin WJ; Zangl LM; Hyun M; Massoud E; Schroeder K; Alexandridis RA; Morris ZS
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.
    Patel RB; Hernandez R; Carlson P; Grudzinski J; Bates AM; Jagodinsky JC; Erbe A; Marsh IR; Arthur I; Aluicio-Sarduy E; Sriramaneni RN; Jin WJ; Massey C; Rakhmilevich AL; Vail D; Engle JW; Le T; Kim K; Bednarz B; Sondel PM; Weichert J; Morris ZS
    Sci Transl Med; 2021 Jul; 13(602):. PubMed ID: 34261797
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Hernandez R; Grudzinski JJ; Aluicio-Sarduy E; Massey CF; Pinchuk AN; Bitton AN; Patel R; Zhang R; Rao AV; Iyer G; Engle JW; Weichert JP
    J Nucl Med; 2020 Aug; 61(8):1187-1194. PubMed ID: 31862799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Characterization of
    Grudzinski JJ; Hernandez R; Marsh I; Patel RB; Aluicio-Sarduy E; Engle J; Morris Z; Bednarz B; Weichert J
    J Nucl Med; 2019 Nov; 60(11):1622-1628. PubMed ID: 30954941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.
    Clark PA; Sriramaneni RN; Bates AM; Jin WJ; Jagodinsky JC; Hernandez R; Le T; Jeffery JJ; Marsh IR; Grudzinski JJ; Aluicio-Sarduy E; Barnhart TE; Anderson BR; Chakravarty I; Arthur IS; Kim K; Engle JW; Bednarz BP; Weichert JP; Morris ZS
    Radiat Res; 2021 Jun; 195(6):522-540. PubMed ID: 33826741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor efficacy of
    Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Hernandez R; Walker KL; Grudzinski JJ; Aluicio-Sarduy E; Patel R; Zahm CD; Pinchuk AN; Massey CF; Bitton AN; Brown RJ; Sondel PM; Morris ZS; Engle JW; Capitini CM; Weichert JP
    Commun Biol; 2019; 2():79. PubMed ID: 30820474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
    Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-Specific Antibody, Cetuximab, Enhances the
    Jin WJ; Erbe AK; Schwarz CN; Jaquish AA; Anderson BR; Sriramaneni RN; Jagodinsky JC; Bates AM; Clark PA; Le T; Lan KH; Chen Y; Kim K; Morris ZS
    Front Immunol; 2020; 11():591139. PubMed ID: 33281820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting.
    Magee K; Marsh IR; Turek MM; Grudzinski J; Aluicio-Sarduy E; Engle JW; Kurzman ID; Zuleger CL; Oseid EA; Jaskowiak C; Albertini MR; Esbona K; Bednarz B; Sondel PM; Weichert JP; Morris ZS; Hernandez R; Vail DM
    PLoS One; 2021; 16(8):e0255798. PubMed ID: 34383787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
    Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
    J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination.
    Carlson PM; Patel RB; Birstler J; Rodriquez M; Sun C; Erbe AK; Bates AM; Marsh I; Grudzinski J; Hernandez R; Pieper AA; Feils AS; Rakhmilevich AL; Weichert JP; Bednarz BP; Sondel PM; Morris ZS
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition.
    Zboralski D; Osterkamp F; Christensen E; Bredenbeck A; Schumann A; Hoehne A; Schneider E; Paschke M; Ungewiss J; Haase C; Robillard L; Simmons AD; Harding TC; Nguyen M
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2621-2635. PubMed ID: 37086273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases.
    Clark PA; Sriramaneni RN; Jin WJ; Jagodinsky JC; Bates AM; Jaquish AA; Anderson BR; Le T; Lubin JA; Chakravarty I; Arthur IS; Heinze CM; Guy EI; Kler J; Klar KA; Carlson PM; Kim KM; Kuo JS; Morris ZS
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
    Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
    Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclotron-Produced
    Aluicio-Sarduy E; Barnhart TE; Weichert J; Hernandez R; Engle JW
    J Nucl Med; 2021 Jul; 62(7):1012-1015. PubMed ID: 33127622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists.
    Filderman JN; Taylor JL; Wang J; Zhang Y; Singh P; Ross MA; Watkins SC; Nedal Al Bzour A; Karapetyan L; Kalinski P; Storkus WJ
    Front Immunol; 2024; 15():1334769. PubMed ID: 38312842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.